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Abstract The main aim of this study was to confirm in an
Italian population affected by tension-type headache (TTH)
the good profile of safety and tolerability of the combination
paracetamol 1,000 mg–caffeine 130 mg (PCF) observed in
previous studies, by a comparison with naproxen sodium
550 mg (NAP) and placebo (PLA). A secondary objective
was to assess the efficacy of PCF in the acute treatment of
TTH. This was a multicentre, randomised, double-blind,
double-dummy, crossover, placebo-controlled trial. Tolera-
bility was assessed by recording adverse events by the patient
in the 4-h post-dose treatment. To assess the efficacy, the sum
of pain intensity differences (SPID) and the total pain relief
(TOTPAR) were calculated. Comparing PCF and NAP and
PCF and PLA for tolerability, the difference was nonsig-
nificant but the result regarding noninferiority was
inconclusive, whilst NAP was noninferior to PLA. As
regards SPID and TOTPAR, both PCF and NAP were better
than placebo (P \ 0.05), but not significantly different from
each other. In conclusion, PCF was well-tolerated and
effective in the treatment of acute TTH.
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Paracetamol  Caffeine  Paracetamol–caffeine
combination  Naproxen sodium
Introduction
Tension-type headache (TTH) is the most prevalent pri-
mary headache with a worldwide lifetime prevalence of
46% [1]. In Europe the lifetime prevalence of TTH seems
to be even higher: it was as high as 86% in a population-
based study in Denmark [2]. Even if in that study most of
the patients had episodic infrequent TTH (1 day or less per
month), nevertheless 24–37% had TTH several times a
month and 10% had TTH weekly. Due to its high preva-
lence, TTH carries a great (and still partially unexplored)
burden for the affected individuals and the society. The
results of two Danish studies have shown that the number
of work days missed in the population owing to TTH was
three times higher than the number for migraine [3, 4]; and
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a US study has also found that absenteeism due to TTH is
considerable [5]. Under the assumption that the indirect
costs of TTH far outweigh the direct costs, we can there-
fore speculate that the cost of TTH is greater than the cost
of migraine [1, 6].
Given the high prevalence and costs of TTH, it is of
paramount importance to have safe, well-tolerated, and
effective drugs to treat TTH at our disposal. Lacking spe-
cific drugs, as triptans are for the acute treatment of
migraine, NSAIDs are commonly employed [7]. Some
NSAIDs have been proved to be superior to placebo in the
acute treatment of TTH [8]. However, gastric irritation and
occasionally ulceration may complicate treatment with
aspirin or other NSAIDs, even when they are used inter-
mittently. The combination of paracetamol and caffeine is
an useful alternative to NSAIDs: it was compared with
placebo in two high-quality studies, showing its superiority
over placebo as well as a good tolerability [9, 10]. Such
studies, however, were carried out in Anglo-Saxon popu-
lations, with different habits respect to Italian patients,
including higher consumption of caffeine, and therefore a
different sensitivity to its peripheral and central stimulatory
effects.
The main aim of this study was to confirm in an Italian
population affected by TTH the good profile of safety and
tolerability of the combination paracetamol 1000 mg–
caffeine 130 mg observed in previous studies [9, 10], by a
comparison with naproxen sodium, a NSAID widely used
in the acute treatment of TTH [11–13], and placebo. A
secondary objective was to assess the efficacy of the
combination paracetamol 1000 mg–caffeine 130 mg in the
acute treatment of TTH, versus naproxen sodium 550 mg
and placebo.
Patients and methods
Patients
In this multicentre study, conducted between December
2004 and May 2007 in eight Headache Centres throughout
Italy, outpatient volunteers of both genders (18–65 years)
with a clinical history of TTH were recruited if they fulfiled
the following inclusion criteria:
• Diagnosis of episodic tension-type headache according
to the ICHD-II criteria [14], modified in the single,
following criterion: absence of nausea, vomiting,
photophobia and phonophobia (to exclude subjects
with migraine headaches),
• Mean frequency of 4–14 days with TTH per month,
• History of response to treatment of TTH with over-the-
counter pain-killers,
• Daily consumption of at least two cups of coffee,
• Adequate contraception in women of fertile age,
• Medical history and physical examination inconsistent
with organic disorders associated with headaches.
Subjects were excluded from the study if they had a
history of any of the following:
• Known hypersensitivity or allergy to paracetamol or
naproxen,
• Chronic headache, either recurrent or continuous,
• Concomitant use/overuse of NSAIDs or other analge-
sics; treatment with antiplatelet or anticoagulant drugs,
• Migraine or post-traumatic headache,
• Alcohol abuse, drug dependency, or psychiatric disease,
• Coagulation disorders, peptic ulcer disease, pancreatic
disease, clinically significant renal or hepatic disease,
blood hypertension, mild/moderate kidney or liver
failure, Gilbert’s syndrome.
The study was conducted in accordance with the Dec-
laration of Helsinki (Tokio version 2004) and Good
Clinical Practice standards and did not start before inde-
pendent Ethics Committee approval appropriate for each
investigator was obtained. Prior to enrolment the patients
gave their written informed consent; they were allowed to
terminate participation in the trial at any time, without
giving reasons. This trail complies with the Guidelines for
trials of drug treatments in TTH of the International
Headache Society [15].
Study design and treatments
This study was designed as a randomised, double-blind,
double-dummy, crossover, placebo-controlled trial. After
having signed the informed consent form, patients were
required to treat the next three consecutive TTH attacks
with the investigational study medications, according to a
randomised crossover sequence which was computer gen-
erated using Microsoft Access 2003. Each patient was
randomly allocated to one of the six sequences illustrated
in Table 1, according to a 1:1:1:1:1:1 scheme. Eligible
patients were assigned in sequential order of entry. Access
to the randomisation code was strictly controlled and the
treatment assignment remained unknown to all parties
involved in the trial until formal database lock. Subjects in
all treatment groups received three identical boxes (num-
bered progressively from 1 to 3 to indicate the exact order
in which they should have been used) containing: one soft
gel capsule containing one tablet of placebo and one sachet
containing paracetamol 1,000 mg ? caffeine 130 mg
[Tachicaf, Angelini Farmaceutici, ACRAF S.p.A.,
Pomezia (RM), Italy] or one soft gel capsule containing
one tablet of naproxen sodium 550 mg (Synflex Forte,
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Recordati S.p.A., Milano, Italy) and one sachet of placebo
or one soft gel capsule containing one tablet of placebo and
one sachet of placebo. The doses corresponded to the
maximal individual therapeutic single doses recommended
for these analgesics. Blinding was ensured using matched
trial supplies, identical in colour, size, shape and taste. At
each TTH attack patients would have to take one soft gel
capsule and one sachet at the same time. The trial medi-
cation was to be taken when the headache occurred, and
when the patients would normally have taken their usual
analgesic. Other than study medication, patients received
rescue medication (ibuprofen 600 mg), to be taken 2 h
after the administration of the trial medication, if the pain
persisted.
At baseline visit, patients’ medical histories and con-
comitant treatments were recorded, vital signs were
registered and physical examination was performed by the
investigator. Patients were required to record in a headache
diary, the date and time of drug ingestion, pain intensity
before treatment and pain intensity, pain relief and adverse
events (AEs) after treatment recorded at 1, 2, 3, and 4 h. At
the end of 4-h measurement interval or at the time of use of
rescue medication, patients had to record the presence and
intensity of AEs and to evaluate their impression of the
efficacy and tolerability of the study medication. The same
procedures were repeated for the two subsequent TTH
attacks, provided that they were 48 h apart from each other.
Patients had to contact the investigator within 48 h after
the third treated episode of TTH for the final visit. The
investigator reviewed the completed diary with the patient
to ensure that all required information had been registered,
recorded vital signs and concomitant treatments and
expressed a global assessment of tolerability. Patients were
asked to indicate their preference for one of the three
treatments, taking into account efficacy and tolerability.
Outcomes
Safety and tolerability were evaluated by comparing vital
signs at screening and final visits and by recording AEs.
AEs could be recorded by the investigator or by the patient
[filling in a symptom check-list (including nervousness,
palpitation, insomnia, dizziness, abdominal pain, dyspep-
sia, nausea, vomiting, drowsiness and fatigue) hourly for
4 h after the study medication ingestion]. AEs intensity
was determined by subjective evaluation of the patient and
classified as mild (signs or symptoms easily tolerated),
moderate (discomfort sufficient to cause interference with
normal activities) and severe (incapacitating with inability
to do work or undertake normal activity). A global
assessment of tolerability was expressed by the patient,
using a 5-point Verbal Rating Scale (VRS: ‘excellent’,
‘very good’, ‘good’, ‘sufficient’ and ‘poor’). The investi-
gator expressed a global assessment of tolerability, using
the following 5-point VRS: ‘very good’ (no AEs), ‘good’
(mild AEs recovered spontaneously without treatment),
‘fair’ (AEs requiring treatment to recover), ‘poor’ (AEs
requiring withdrawal from study), ‘very poor’ (serious
AEs).
To assess treatments’ efficacy, intensity of pain (on a
4-point scale: 0 ‘absent’, 1 ‘mild’, 2 ‘moderate’, 3 ‘severe’)
and pain relief (on a 5-point scale: 0 ‘no relief’, 1 ‘little
relief’, 2 ‘some relief’, 3 ‘much relief’, 4 ‘complete relief’)
were evaluated hourly during the 4-h post-dose period.
Based on these two variables, the following parameters
were calculated:
– Pain intensity difference (PID). For each patient the
sum of pain intensity differences (SPID) was calculated
as the sum of differences between pre-dose assessment
and every post-dose assessment,
– Total pain relief (TOTPAR), calculated as the sum of
every post-dose assessment.
Finally, patients expressed their preference for one of
the investigational treatments, answering the following
question: ‘‘Taking into account both tolerability and effi-
cacy, which of the three treatments would you take again at
the next headache attack?’’ (Options were: (a) none, (b)
treatment number 1, (c) treatment number 2, (d) treatment
number 3).
Statistical analysis
The study was powered to test the primary hypothesis,
namely that paracetamol 1,000 mg ? caffeine 130 mg
(PCF) would be non-inferior to naproxen sodium 550 mg
(NAP) as regards the proportion of patients complaining of
AEs in the 4-h post-dose period. Assuming a 7% threshold
as the maximum tolerated difference between PCF and
NAP, a 7.9% proportion of discordant pairs, 80% power,
and one-tailed test with a 0.05 significance level, the
required sample size was estimated to be 100 treated
patients. In order to take any premature withdrawals into
account, the number of patients to be enrolled was set at
150.
According to study protocol, three populations have
been evaluated: per-protocol (PP, subjects fulfiling all the
inclusion criteria who took the three treatments and
Table 1 Sequences of study
treatments
PCF paracetamol
1,000 mg ? caffeine 130 mg,
NAP naproxen sodium 550 mg,
PLA placebo
1. PCF–NAP–PLA
2. NAP–PLA–PCF
3. PLA–PCF–NAP
4. PCF–PLA–NAP
5. NAP–PCF–PLA
6. PLA–NAP–PCF
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performed all the tolerability evaluations), randomized
patients (RP, patients who took at least one of the treat-
ments), and intention-to-treat [ITT, patients who took the
three treatments and performed at least one post-dose
evaluation. Data missing for any scheduled evaluation was
replaced by the last observation carried forward (LOCF)
procedure]. The tolerability endpoints were evaluated using
PP and RP populations; ITT population was employed for
efficacy analyses. Descriptive statistics on RP population
was used for demographic and baseline characteristics.
The Mc Nemar test (reported as 90% confidence inter-
val) was used to compare the percentage of patients who
recorded AEs after each treatment. Besides those recorded
by patients in the 4-h post-dose period, all the AEs were
classified by the investigator on the basis of: treatment
received, system involved, severity and correlation with the
investigational medication. The analysis of variance was
used to evaluate the differences of vital signs respect to
baseline. The Wilcoxon signed rank test was used to ana-
lyse the global assessment of tolerability expressed by
patients.
The analysis of variance was used to evaluate SPID and
TOTPAR. The patient’ preference for one of the treatments
was reported as a distribution of frequency.
The evaluation of the quality and completeness of the
data, identification of important protocol deviations and
handling of problem cases were performed regularly and
finally decided before locking and unblinding the database.
Results
Study population
One-hundred and eleven subjects entered the study, 99 of
whom took at least one of the treatments (RP). Twelve
patients were excluded from the study, since they did not
fulfil the inclusion criteria (n = 2) or did not take any
medication (n = 10). Other six patients took 1 or 2
investigational medications only. Therefore PP population
included 93 subjects. Reasons why patients did not com-
plete the study were: explicit request to withdraw from the
study (n = 8), lack of compliance to study procedures
(n = 5), severe nausea (n = 1), unmasking of assigned
treatment (n = 1), expiry of investigational medication
(n = 1). ITT population included 93 subjects, 91 and 81 of
whom were available for the efficacy analyses concerning
pain severity and pain relief, respectively.
Demographic characteristics and headache history of RP
population are shown in Table 2. As regards baseline pain
intensity of treated headaches (n = 287), 47 attacks
(16.4%) were judged to be mild, 168 (58.5%) moderate and
72 (25.1%) severe.
Tolerability and safety
Considering the PP population (n = 93), in which all the
tolerability assessments were available, the following per-
centages of patients reported AEs in the 4-h post-dose
period: 36.6% with PCF, 31.2% with NAP, and 36.6% with
placebo (PLA). Comparing PCF and NAP, the proportion of
discordant pairs (that is, patients who reported AEs with one
but not the other drug and vice versa) were 19.4 and 14.0%,
respectively, with a difference of 5.4% (90% CI, -4.4 to
15.2%). Comparing PCF and PLA, the proportion of dis-
cordant pairs was 14.0% for both treatments, with no
differences of discordant pairs (90% CI, -9.0 to 9.0%).
Since in the comparisons PCF–NAP and PCF–PLA the
confidence interval included both D (the maximum tolerated
difference between treatments) and zero, the difference was
nonsignificant but the result regarding noninferiority was
inconclusive [16]. Comparing NAP and PLA, the proportion
of discordant pairs were 12.9 and 18.3%, respectively, with a
difference of -5.4% (90% CI, -14.9 to 4.1%). Therefore
NAP was noninferior to PLA. During the 4-h post-dose
period, 224 AEs were recorded in the RP population, 76
(33.9%) after PCF ingestion, 66 (29.5%) after NAP and 82
(36.6%) after PLA. Table 3 illustrates the percentage of AEs
according to investigational drugs. Most AEs were codified
as mild or moderate. Only 21 AEs (9.4%) were recorded as
severe: 13 (5.8%) after PLA, 5 (2.3%) after NAP and 3
(1.3%) after PCF. The most frequently observed AEs were
nausea, drowsiness, fatigue and nervousness (Table 3).
Table 2 Demographic characteristics and headache history (ran-
domized patients dataset; n = 99)
Gender, n (%)
Male 40 (40.4)
Female 59 (59.6)
Age, years
Mean ± SD 35.1 ± 10.19
Range 19–64
Race, n (%):
Caucasian 98 (99.0)
Other 1 (1.0)
Headache duration, years
Mean ± SD 22.2 ± 9.09
Range 6–44
Mean number of days with tension-type headache per month, n (%)
\4 2 (2.0)
4–14 97 (98.0)
[14 –
Usual pain intensity, n (%)
Mild 21 (21.2)
Moderate 75 (75.8)
Severe 3 (3.0)
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Besides AEs directly recorded by the patients, other 20
AEs were registered by the investigator. Only two of them
(sweating and lips dryness), however, were judged to be
possibly correlated to the drug. No serious AEs occurred.
One patient dropped from the study because of severe
nausea during a headache attack treated with PCF. No
significant differences occurred in vital signs recorded at
final visit compared to those recorded at screening visit.
The global assessment of tolerability expressed by the
patient is shown in Table 4. The evaluation was ‘excellent’
or ‘very good’ in 45.7% of the patients after PCF, in 51.6%
after NAP, and 41.7% after PLA. The difference was sta-
tistically significant (P \ 0.05) between NAP and PLA.
The global assessment of tolerability expressed by the
investigator on the RP population (n = 97) at the final visit
and referring to the sum of investigational drugs, gave the
following results: ‘very good’ or ‘good’ in 96%, ‘fair’ in
3% and ‘poor’ in 1% of the patients.
Efficacy
Figure 1 reports the time course of PID for the three
investigational treatments, whilst the SPID mean values
with standard errors are illustrated in Table 5. PID relative
to baseline steadily increased over time in both the active
treatments compared to placebo. PCF and NAP were sig-
nificantly better than placebo (P \ 0.05), whilst no
differences emerged between the two active treatments.
The time course of TOTPAR during the 4-h observation
period is shown in Fig. 2, whilst TOTPAR mean values with
standard errors are displayed in Table 5. Both PCF and NAP
provided significantly more relief than placebo (P \ 0.05),
but were not significantly different from each other.
The percentage of subjects using rescue medication was
similar for PCF and NAP (4.8 and 3.3%, respectively) and
both were less than the 10.0% of subjects who used rescue
medication after PLA.
As regards the patients’ preference for one of the tested
treatments (RP dataset, n = 92), 30 patients (32.6%) pre-
ferred PCF, 41 patients (44.6%) NAP and 21 patients
(22.8%) PLA.
Table 3 Adverse events recorded in 4-h period after ingestion of
investigational drugs (randomized patients dataset; n = 99)
Adverse event PCF n (%) NAP n (%) PLA n (%)
Nervousness 11 (14.5) 8 (12.1) 12 (14.6)
Palpitation 4 (5.3) 2 (3.0) 3 (3.7)
Insomnia 4 (5.3) 3 (4.6) 3 (3.7)
Dizziness 6 (7.9) – 4 (4.9)
Abdominal pain 5 (6.6) 4 (6.1) 5 (6.1)
Dyspepsia 6 (7.9) 7 (10.6) 5 (6.1)
Nausea 15 (19.7) 15 (22.7) 21 (25.6)
Vomiting 2 (2.6) 3 (4.6) 2 (2.4)
Drowsiness 11 (14.5) 14 (21.2) 13 (15.9)
Fatigue 12 (15.8) 10 (15.2) 14 (17.1)
PCF paracetamol 1,000 mg ? caffeine 130 mg (n = 98), NAP
naproxen sodium 550 mg (n = 94), PLA placebo (n = 98)
Table 4 Global assessment of tolerability expressed by the patient
(randomized patients dataset)
PCF n (%) NAP n (%) PLA n (%)
Excellent 17 (18.1) 32 (35.2) 20 (20.8)
Very good 26 (27.7) 15 (16.5) 20 (20.8)
Good 26 (27.7) 23 (25.3) 22 (22.9)
Sufficient 12 (12.8) 9 (9.9) 14 (14.6)
Poor 13 (13.8) 12 (13.2) 20 (20.8)
Total 94 (100.0) 91 (100.0) 96 (100.0)
PCF paracetamol 1,000 mg ? caffeine 130 mg, NAP naproxen
sodium 550 mg, PLA placebo
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Fig. 1 Time course of the mean pain intensity difference (PID) for
the three investigational treatments (intention-to-treat dataset,
n = 91). PCF paracetamol 1,000 mg ? caffeine 130 mg; NAP
naproxen sodium 550 mg, PLA placebo
Table 5 Sum of pain intensity differences (SPID) and total pain
relief (TOTPAR) in the 4-h observation period (intention-to-treat
dataset)
PCF NAP PLA
SPID
n 91 91 91
Baseline intensity (SE) 2.0 (0.06) 2.1 (0.07) 2.1 (0.08)
Mean (SE) 4.0 (0.35) 4.2 (0.38) 2.1 (0.35)
TOTPAR
n 81 81 81
Mean (SE) 8.5 (0.60) 8.0 (0.63) 4.8 (0.60)
PCF paracetamol 1,000 mg ? caffeine 130 mg, NAP naproxen
sodium 550 mg, PLA placebo
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Discussion
In a condition as widespread as TTH is, using the most
effective dose of a drug that is well tolerated by a patient
(and safe) is a reasonable basis for selecting a medication.
Exerting its analgesic activity thanks to a direct effect on
the central nervous system [17], at least in part mediated by
the serotonergic system [18, 19], paracetamol has some
advantages over NSAIDs, due to its scarce inhibition of
peripheral cyclooxygenase: it is well tolerated at gastro-
intestinal level, it is only a weak inhibitor of aggregation of
platelets and does not alter the bleeding time [20]. In a
recent systematic review on the therapy of acute episodic
TTH [7], paracetamol 1,000 mg was significantly more
effective than placebo with AEs matching those of placebo.
A quantitative analysis of seven studies comparing NSA-
IDs and paracetamol, however, showed a significant
difference in short-term pain relief in favour of NSAIDs
[7]. The combination paracetamol 1,000 mg and caffeine
130 mg has been proved to be superior both to placebo and
paracetamol 1,000 mg in the treatment of TTH [10], at no
significant cost in term of AEs, thanks to the synergistic
effect of caffeine. Caffeine has a direct analgesic effect not
mediated via effects on mood or on caffeine withdrawal
[9]. Suggested, albeit unproven, mechanisms for caffeine
analgesia are the antagonistic activity on adenosine
receptors [21] and the ability to increase the norepinephrine
activity in the central nervous system [22]. Moreover,
caffeine has a well-documented adjuvant action, when
combined with analgesics [23]. The mechanisms of this
analgesic adjuvant effect are not well-established, but
could, at least partially, be explained by pharmacokinetic
interactions, in terms of increased absorption or reduced
metabolism of analgesics induced by caffeine [24, 25].
Whatever the mechanisms are, it has been shown that the
addition of caffeine to a NSAID increases its analgesic
potency by 40% [26].
Some worry as far as Italy is concerned could be raised
by the fact that the studies on the ‘high-dose’ paracetamol–
caffeine combination (i.e., paracetamol 1,000 mg and
caffeine 130 mg) were carried out in Anglo-Saxon popu-
lations, with a consumption of caffeine higher than that
found in Italians, and therefore theoretically less prone to
the stimulating effects of caffeine. The results of the present
study are absolutely reassuring about the tolerability of the
paracetamol–caffeine combination. The difference amongst
treatments was nonsignificant, even though the noninferi-
ority of PCF compared to NAP and PLA could not be
conclusively demonstrated. Moreover, the percentage of
patients complaining of AEs in the 4-h post-treatment per-
iod was exactly the same (36.6%) after PCF and after PLA.
The AEs theoretically attributable to the stimulating effect
of caffeine (nervousness, palpitation and insomnia) were
roughly the same with the three investigational medications
(Table 3). The high frequency of some, even severe, AEs
like nausea after PLA is likely to be due to symptoms
accompanying headache not extinguished by the active
drugs. It is not a chance that a good evaluation in the global
assessment of tolerability expressed by the patient was
lower after PLA than after active drugs.
As regards the efficacy, this study confirms the good
results obtained in previous clinical trials [9, 10], showing
a significant superiority of PCF over placebo, and no dif-
ference compared to a reference drug as NAP, in both the
reduction of pain intensity and the pain relief.
The results of this trial may have important implications
for clinical practice. Many drugs for the treatment of TTH
are expensive and/or have contraindications or relevant
side effects [27]. The combination of paracetamol
1,000 mg and caffeine 130 mg seems to be effective and
well tolerated, in particular not showing the specific stim-
ulatory effects of caffeine. It is therefore a serious
candidate for the first line treatment of acute episodic TTH.
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